- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
- ProQR Therapeutics Provides Update on Ophthalmic Assets
- ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
More ▼
Key statistics
On Wednesday, ProQR Therapeutics NV (PRQR:NAQ) closed at 2.38, 114.41% above the 52 week low of 1.11 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.40 |
---|---|
High | 2.44 |
Low | 2.36 |
Bid | 2.19 |
Offer | 2.47 |
Previous close | 2.38 |
Average volume | 204.07k |
---|---|
Shares outstanding | 81.35m |
Free float | 63.00m |
P/E (TTM) | -- |
Market cap | 193.55m USD |
EPS (TTM) | -0.3759 USD |
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼